

RESEARCH ARTICLE

Open Access



Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level

G. E. Calabrò¹, G. La Torre², C. de Waure^{1,3*} , P. Villari², A. Federici⁴, W. Ricciardi¹ and M. L. Specchia¹

Abstract

Background: In an era of a growing economic pressure for all health systems, the interest for “disinvestment” in healthcare increased. In this context, evidence based approaches such as Health Technology Assessment (HTA) are needed both to invest and to disinvest in health technologies. In order to investigate the extent of application of HTA in this field, methodological projects/frameworks, case studies, dissemination initiatives on disinvestment released by HTA agencies and organizations located in Europe were searched.

Methods: In July 2015, the websites of HTA agencies and organizations belonging to the European network for HTA (EUnetHTA) and the International Network of Agencies for HTA (INAHTA) were accessed and searched through the use of the term “disinvestment”. Retrieved deliverables were considered eligible if they reported methodological projects/frameworks, case studies and dissemination initiatives focused on disinvestment in healthcare.

Results: 62 HTA agencies/organizations were accessed and eight methodological projects/frameworks, one case study and one dissemination initiative were found starting from 2007. With respect to methodological projects/frameworks, two were delivered in Austria, one in Italy, two in Spain and three in U.K. As for the case study and the dissemination initiative, both came from U.K. The majority of deliverables were aimed at making an overview of existing disinvestment approaches and at identifying challenges in their introduction.

Conclusions: Today, in a healthcare context characterized by resource scarcity and increasing service demand, “disinvestment” from low-value services and reinvestment in high-value ones is a key strategy that may be supported by HTA. The lack of evaluation of technologies in use, in particular at the end of their lifecycle, may be due to the scant availability of frameworks and guidelines for identification and assessment of obsolete technologies that was shown by our work. Although several projects were carried out in different countries, most remain constrained to the field of research. Disinvestment is a relatively new concept in HTA that could pose challenges also from a methodological point of view. To tackle these challenges, it is necessary to construct experiences at international level with the aim to develop new methodological approaches to produce and grow evidence on disinvestment policies and practices.

Keywords: Disinvestment, Health technology assessment, Healthcare, Low-value, Disinvestment policy implementation, Resource allocation, Priority-setting, Decision-making

* Correspondence: Chiara.DeWaure@unicatt.it; chiara.dewaure@unipg.it

¹Institute of Public Health, Section of Hygiene, Catholic University of the Sacred Heart, L.go F. Vito 1, 00168 Rome, Roma, Italy

³Department of Experimental Medicine, University of Perugia, via Gambuli 1, 06132 Perugia, Italy

Full list of author information is available at the end of the article



© The Author(s). 2018 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.

Background

Around the world, every healthcare system is struggling with rising costs and decision makers are endeavoring to improve system efficiency and to ensure more effective and safe access to care [1]. Therefore, getting high value for patients must become a priority of healthcare delivery and this goal must belong to all stakeholders of the system. Improving health value not only will benefit patients and providers but it will result in increased economic sustainability of healthcare systems. To this aim, it is necessary to pursue a patient-centered system [2] and to foster the transformation to value-based healthcare within the organizations [3]. Therefore, a necessary goal for modern healthcare systems is to disinvest from low-value health technologies and to reinvest in high-value ones. Health technologies include different kinds of interventions (e.g. drugs, devices, medical and surgical procedures, and healthcare organizational and managerial systems) and represent a major driver of costs for healthcare systems [4].

In this value-based context and in an era of a growing economic pressure for all health systems, the interest for “disinvestment” in healthcare increased. Disinvestment is defined as “withdrawing health resources from any existing health care practices, procedures, technologies or pharmaceuticals that are deemed to deliver little or no health gain for their cost, and thus do not represent efficient health resource allocation” [5]. These actions are relevant for the sustainability of health systems because of growing demand for healthcare services, increasing availability of innovative and expensive health technologies and resource constraints. In order to tackle these challenges, evidence based approaches, such as Health Technology Assessment (HTA), are needed both to invest and to disinvest in health technologies. HTA is defined as “a multidisciplinary process that summarizes information about the medical, social, economic and ethical issues related to the use of a health technology in a systematic, transparent, unbiased, robust manner. Its aim is to inform the formulation of safe, effective, health policies that are patient focused and seek to achieve best value” [6]. HTA is an instrument supporting policy-making and is widely applied to govern the drugs market, particularly with respect to the introduction of new medicines. Anyway, in the last few years, the interest in the assessment of health technologies during their whole life cycle increased. This also led to an increasing interest into the application of HTA for disinvesting from little or no benefit technologies [7]. This interest was witnessed by the appearance of the topic of HTA for disinvestment on PubMed in the last decade even though with a low number of publications. Governmental and non-governmental agencies and organizations are entrusted to perform HTA at national and regional level

across Europe and worldwide and are common forerunners of the development of innovations in the field. In order to investigate the extent of application of HTA in disinvestment at the level of HTA agencies and organizations located in Europe, methodological projects/frameworks, case studies, dissemination initiatives on disinvestment developed and released by the latter were searched.

Methods

In July 2015, the websites of all the HTA agencies and organizations belonging to the European network for Health Technology Assessment (EUnetHTA) and the International Network of Agencies for Health Technology Assessment (INAHTA) were accessed and searched entering the term “disinvestment” in the query box. Retrieved deliverables were considered eligible if they reported methodological projects/frameworks, case studies, dissemination initiatives focused on disinvestment in healthcare and if they were published in English or Italian. Deliverables were not considered eligible if disinvestment was not the major topic or was addressed only in a narrative way. The following data were collected for each eligible deliverable: agency which released the deliverable; title of the methodological project/framework, case study, dissemination initiative; type of deliverable (i.e. position paper; methodological document; project; article; workshop); status of the deliverable (i.e. ongoing; closed); year; working group/authors; aim; field of application; methods; results and recommendations; identification of potential objectives of disinvestment. The screening process and the extraction of data were performed independently by two researchers and disagreements were solved through a consensus.

Results

Selection process and deliverables characteristics

A total number of 62 HTA agencies and organizations were searched. Additional file 1: Table S1 shows the list.

All the websites were accessible except for three. Out of 61 deliverables retrieved from the search, only ten met the inclusion criteria. The ten deliverables were released from 2007 onwards. They generally were relied on systematic reviews of the literature or questionnaires/interviews or data collection and analysis. The majority of deliverables were just aimed at making an overview of existing approaches and to identify challenges that might delay the introduction of disinvestment practices. Eight of them may be classified as methodological projects/frameworks [8–15], one as a case study [16] and one as a dissemination initiative [17]. All of them were closed at the time of the search except for one [10].

All the details regarding the ten deliverables are reported in the Additional file 2: Table S2.

Methodological projects/frameworks

As for methodological projects/frameworks, two were delivered by the *Ludwig Boltzmann Institute for Health Technology Assessment* (LBI-HTA) in Austria [8, 9], one by the *Agency for Regional Healthcare* (Age.Na.S) in Italy [10], two from *Galician Agency for Health Technology Assessment* (AVALIA-T) [11] and *Agència de Qualitat i Avaluació Sanitàries de Catalunya* (AQuAS) [12] in Spain, one from the *Evaluation, Trials and Studies Coordinating Centre* (NETSCC-NIHR) [13] and two from the *Healthcare Improvement Scotland* (HIS) [14, 15] in U.K.

Deliverables released by LBI-HTA (Austria) were two systematic reviews. The first [8] was conducted in April 2011, assessing four scientific databases, websites of HTA agencies and grey literature. Policies on disinvestment from potentially obsolete technologies were the focus of the research. The aim of the review was to offer an ample overview of current disinvestment approaches of some countries (England, Spain, Australia and Canada) in order to identify the main challenges that might delay introduction of disinvestment practices in different settings and to develop recommendations for the winning achievement of disinvestment strategies. The overview of 31 articles showed that disinvestment policies in England, Spain, Australia and Canada were ongoing. The only country at a more advanced stage was Spain that had an official methodological framework – the Guideline for Not Funding existing health technologies. Instead, in England, the National Institute for Health and Care Excellence (NICE) was known issuing obligatory disinvestment advices. In Australia and Canada a dynamic debate on implementation of disinvestment policy was found, but most of the projects were yet in a piloting phase at regional level. A standard methodology of HTA for disinvestment activities was identified in all organizations studied. Nevertheless, there were not significant disinvestment projects conducted, therefore authors concluded that assessment of methods was not possible and future evidence will serve in order to evaluate whether HTA methodology for disinvestment is adequate or new methods need to be built. Furthermore, dissemination of disinvestment recommendations was considered decisive in all countries. Conversely no explicit strategies for the application of disinvestment results were proposed.

The second review of 2013 [9] was relied on five scientific databases and was aimed to identify articles describing internationally developed and implemented models for the recognition of unproductive interventions and technologies. Websites of HTA agencies, Google and relevant journals were hand searched to retrieve further information. International experts were also involved through a survey. On the basis of the results of the literature review (120 documents) and of questionnaires,

eight implemented models were identified. The analysis showed that there were commonalities concerning objectives, involvement of stakeholders and choice of target groups. Most models identified ineffective interventions and technologies using person- and literature-based information sources. Effectiveness, costs and benefit were commonly applied as identification criteria. Physicians, patients and HTA-researchers were involved. Outputs – mostly HTA reports or lists – were generally distributed via internet. Recommendations were implemented either as compulsory guidelines or as non-binding information for practitioners and other stakeholders. Nevertheless, data to appraise the actual impact of models useful to identify inefficient interventions and technologies were missing.

Two HTA agencies/organizations, Age.Na.S and AVALIA-T, were involved in delivering/proposing a guide/approach to promote disinvestment. Nonetheless, the project carried out by Age.Na.S started in 2012 and was still ongoing at the time of the search, whereas the one from AVALIA-T was closed.

The Italian project was concluded in 2015 and the results were recently published [10]. The aim of the project was to develop a systematic and integrated approach to identify obsolete health technologies and to plan the implementation of new technologies in specific sectors such as: an organized screening program for HPV cervical cancer as a primary test, diagnostic imaging technologies, medical interventions and specific telemedicine applications.

The emerged crucial aspects to be considered were the following: the identification of the health needs, the obsolescence of technology, the involvement of professionals in the choices, the careful analysis of the preventive context of both investment and disinvestment and the monitoring of the effects of such choices. Concerning these aspects, the project concluded with the proposal of some concretely implementable tools represented by:

- a procedure for the identification by an expert panel of interventions/procedures to be divested, starting from the systematic review of the scientific literature;
- a computerized procedure to induce professionals to identify discarded technologies according to a multi-criteria decision model;
- the methodology to analyze a regional technological park based on the assessment of the degree of obsolescence and productivity and of potential innovation;
- the methodology of ex-post evaluation of investment / renewal interventions;
- guidelines on the implementation of an innovation with the simultaneous disposal of the current alternative (i.e. the DNA-HPV test as a primary test in the Italian programs for cervical cancer screening).

The Spanish Agency AVALIA-T conducted a literature review until April 2009 in specialized databases [11], with particular attention at webpages of different national HTA agencies and government bodies, for the most part in the area of health services research. The research was focused on obsolete health technologies, including their limits and benefits. The produced guide consisted of three different sections for identification, prioritization and assessment of potentially obsolete technologies. In the first section (identification), potential sources were established: 1) direct consultation of medical literature; 2) consultation of new and rising technology databases (i.e. EuroScan); 3) consultation of systematic reviews published from scientific literature or assessment agencies; and, 4) consultation with administrative offices that are upgraded to the National Health System, hospital or regional service portfolios. After the identification, the assessment agencies would apply a standardized process to validate that the identified technology could be labeled as potentially obsolete and prioritized. In the second chapter (prioritization), a specific tool developed by AVALIA-T (PriTec tool) to prioritize potentially obsolete health technologies for following assessment was described. This tool consisted of three domains (population/end-users; risk/benefit; costs, organization and other implications) with a total of ten criteria with specific weights. Furthermore, a free of charge web application in Spanish and English was released (<http://avalia-t.sergas.es/> or <http://www.pritectools.es/index.php?idioma=en> or www.pritectools.es) enabling up to 50 potentially obsolete health technologies to be confronted and prioritized in order to be evaluated. The final section proposed a pilot structure for the assessment of potentially outdated technologies, with a focus on the comparison of obsolete technologies with alternative ones. To assess a potentially obsolete technology, an assessment document was planned, with specific sections, focused on comparison of the benefits (in terms of efficacy, safety, efficiency, costs and other consequences) of the potentially obsolete versus the proposed alternative technology.

The second project conducted in Spain by AQUAS was published on *Health Policy* in 2013 [12]. In this paper a frame of disinvestment strategies with a “value for money” approach was proposed. Based on the experiences of other countries, it reviewed the existing instruments for implementing this approach in the Spanish National Health Service (SNS). Articulating the proposed approach to “value for money” would require three basic elements: (A) a regulatory framework, (B) the ability to identify “low value” interventions and create a guide on best practice, (C) the capacity to check compliance to and effects of “enforced” guide. Although these elements were present in the SNS from various

years, their effective use in supporting a disinvestment strategy met numerous obstacles. To overcome them, the authors suggested to pool together experiences and tools and to design a process following these steps: identifying a set of “low value” procedures and their more cost-effective alternatives; mapping unjustifiable variations in the use of the selected procedures across the SNS; conforming a web-based tool for customized variability analysis to take into account excess-use and excess-costs of low value procedures in different decision-making contexts.

Three deliverables were released in U.K. [13–15]. A project was conducted by the NETSCC-NIHR in order to develop a process allowing policy-makers identifying existing procedures with uncertain appropriateness. The other two projects were conducted by HIS in 2012 and 2013 respectively. The first work was carried out by a group named *Making Choices Spending Wisely- MaCS-Wise*, interested in investment and disinvestment and belonging to the Scottish Health Technologies Group (SHTG). The SHTG was established by the Scottish Government Health Directorates (SGHD) and is an advisory group that aims to offer support and assistance to NHS boards when taking into consideration the introduction of new technologies to NHSScotland assessed by NICE and other HTA organizations in the U.K. and internationally. The aim of the project was to review the cost saving guidance and the ‘do not do’ recommendations released from NICE with regard to NHSScotland. Recommendations were identified that were thought to be easy to implement, likely to achieve cost savings and not requiring additional investment. Specifically, the obtained data indicated that NICE cost-saving recommendations identified from cancer guidelines were current clinical practice in the majority of NHS boards in Scotland.

The second project of HIS was undertaken to ascertain the quantity and quality of the published evidence on disinvestment. A search was carried out in the Cochrane library, NHS Economic Evaluation Database and Medline to identify relevant documents published up to July 2012. This was supplemented by general web searching, and backward and forward citation searching from included references. Articles discussing or assessing approaches used to obtain or incorporate public opinion when making any decisions relating to disinvestment were selected. Only five articles discussed frameworks, policies, processes or methods that were developed and used to obtain, consider or incorporate the views of the public during the disinvestment process. The review showed that limited research was done to discover the most suitable ways to involve the public in the decision-making process on disinvestment. The majority of articles reported that additional effort was needed to allow the public to increase and communicate informed views,

and consequently to include these views during the decision-making process on disinvestment.

Case studies and dissemination initiatives

In addition to the deliverables described, one case study and one dissemination initiative were found on the topic of disinvestment [16, 17]. The first one came from the NICE [16] whereas the second from HIS [17] in U.K. The case study was started in 2007 and it is still ongoing, while the dissemination initiative was conducted in 2013.

The “do not do recommendations” database [16] should be mentioned because it identifies and collects all recommendations about NHS clinical practices to be stopped completely or not used in daily practice. In fact, the database included more than 90 recommendations on different topics, among which: cancer care; blood and immune system conditions; cardiovascular conditions; diabetes and metabolic disorders; gastrointestinal diseases; fertility, pregnancy and childbirth; genetic diseases. Instead, the dissemination initiative was related to the organization of a session on disinvestment in a workshop realized by the SHTG team of HIS.

Discussion

This work aimed to summarize the existing projects, frameworks, case studies and initiatives on disinvestment developed and released by HTA agencies and organizations located in Europe. Indeed, this review broadens the knowledge of disinvestment activities in Europe collating together not only projects in the field but also other types of initiatives, such as real life applications or dissemination actions. A total number of 62 HTA agencies and organizations were accessed and eight methodological projects/frameworks, one case study and one dissemination initiative were found starting from 2007.

With respect to methodological projects/frameworks, two were delivered in Austria, one in Italy, two in Spain and three in U.K. As for the case study and the dissemination initiative, both came from U.K. The majority of deliverables were aimed at making an overview of existing disinvestment approaches and to identify challenges in their introduction. Two HTA agencies/organizations, Age.Na.S and AVALIA-T, were involved in delivering/proposing a guide/approach to promote disinvestment. Age.Na.S and AVALIA-T frameworks both calls for the involvement of multiple stakeholders and for the assessment of available evidence in order to identify potential obsolete technologies. Furthermore, both frameworks rely on a multi-criteria decision analysis. Nevertheless, AVALIA-T delivered a more structured framework enclosing a tool for conducting the assessment. In particular, AVALIA-T proposed a framework for the

identification, prioritization and assessment of potentially obsolete technologies used in healthcare.

Further deliverables assessed clinical practice, evaluating adherence to recommendations/guidelines and making benchmarking. In particular, one project from HIS assessed the adherence to NICE “do not do” recommendations. The case study, the “do not do recommendations” database, is to be considered as a best example identifying and collecting recommendations about clinical practices to be discontinued or not used routinely.

Despite the great interest in the field of disinvestment in healthcare, the identification of a “disinvestment framework” at an international level that could be considered a gold standard is a critical issue. Spain was the only country that had a formal methodological framework but further evidence is needed to assess its implementation and impact also outside Spain. The attention paid to the topic by the scientific community calls for the development of frameworks for disinvestment and for their real-world implementation as the main challenge.

Limited resources and increased demand for services lead healthcare systems to do choices within bound budgets underlying the need for prioritization. In fact, health systems have to allow access to effective, safe and efficient care. Priority setting may help health systems to make decisions about services to be funded or not. In this context, ‘disinvestment’ from low-value services and reinvestment in high-value ones is a key strategy which may be supported by HTA [18]. The issue of disinvestment emerged from existing HTA activities and concerns the assessment of technologies in their last phase of lifecycle. The disinvestment supported by HTA methodology started earning consideration as a policy approach for more efficient allocation of healthcare resources [8]. However, many current technologies were never assessed neither at their launch nor in their implementation phase. The lack of assessment, in particular at the end of the lifecycle, may be due also to the scant availability of frameworks and guidelines for identification and assessment of obsolete technologies that was shown by our work. Future research should address the issue of developing and testing a standardized method across European countries. In fact, although several projects were carried out in different countries, most remain constrained to the field of research. Important initiatives, for example, were conducted outside Europe, namely in Australia and New Zealand. A workshop, titled ‘Disinvestment is not a dirty word’, was held by the Health Policy Advisory Committee on Technology (HealthPACT) and supported by South Australia’s Chief Medical Officer in Brisbane on 17 May 2013. It focused on national and local disinvestment activities and the related challenges for physicians, health policy makers and funders. A report was subsequently published [19]. The

following practical proposals came from this initiative: to offer advice, as appropriate, as a standing committee of the Australian Health Ministers' Advisory Council's Hospitals Principal Committee; to support disinvestment opportunities at national and local levels; to supply a national depository for disinvestment programs in order to guarantee pertinent information to be disclosed and to enable dialogue.

Nonetheless, detecting and eliminating potentially obsolete health technologies is a complex process that requires inputs from all relevant stakeholders, including the public and citizens, but coordinated efforts in educating all key stakeholders are necessary [18]. HTA plays a key role in favoring an evidence-based approach to pursue safety, quality, and appropriate allocation of resources and it can support the disinvestment process in healthcare [7].

Some limitations of this study need to be considered when interpreting the findings. Firstly, although the search was very wide in terms of sources, the websites of all the HTA agencies and organizations were searched using the nonspecific keyword "disinvestment". Moreover, our search summarized methodological projects/frameworks, case studies and dissemination initiatives of HTA agencies and organizations but it excluded other works in the scientific literature or present in other databases. Hence, we found a rather small number of deliverables in line with our criteria, and this clearly led to a limited analysis of the European experiences on the field of disinvestment. Nonetheless, this study represents the first overview of HTA agencies and organizations activities trying to identify and describe the actions at European level on disinvestment in healthcare.

Conclusion

Disinvestment is a relatively new concept in HTA that could pose challenges also from a methodological point of view. To tackle these challenges, it is necessary to go on with international experiences focused on rising novel practical approaches to generate evidence and tools for disinvestment policies and practices.

Additional files

Additional file 1: Table S1. List of HTA bodies and organizations belonging to INAHTA and EUnetHTA which have been consulted (PDF 263 kb)

Additional file 2: Table S2. Details regarding the methodological projects/frameworks, case studies and dissemination initiatives selected (DOCX 30 kb)

Abbreviations

Age.Na.S: Agency for Regional Healthcare; AQUAS: Agència de Qualitat i Avaluació Sanitàries de Catalunya; AVAIA-T: Galician Agency for Health Technology Assessment; EUnetHTA: European network for Health Technology Assessment; HealthPACT: Health Policy Advisory Committee on Technology; HIS: Healthcare Improvement Scotland; HTA: Health Technology

Assessment; INAHTA: International Network of Agencies for Health Technology Assessment; LBI-HTA: Ludwig Boltzmann Institute for Health Technology Assessment; MaCSWise: Making Choices Spending Wisely; NETSCC-NIHR: Evaluation, Trials and Studies Coordinating Centre; NICE: National Institute for Health and Care Excellence; SGHD: Scottish Government Health Directorates; SHTG: Scottish Health Technologies Group; SNS: Spanish National Health Service

Acknowledgements

The project is a part of the activities funded under the Italian National Centre for Disease Prevention and Control in order to support the Ministry of Health in coordinating and implementing the workpackage 5 of the European Joint Action CanCon.

Availability of data and material

All data analysed during this study are included in this published article.

Funding

The project is a part of the activities funded under the Italian National Centre for Disease Prevention and Control in order to support the Ministry of Health in coordinating and implementing the workpackage 5 of the European Joint Action CanCon.

Authors' contributions

GEC, MLS and CdW made substantial contributions to conception and design of the study, acquisition, analysis and interpretation of data and drafting the article. GLT, PV, AF and WR revised the article critically and give final approval of manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

¹Institute of Public Health, Section of Hygiene, Catholic University of the Sacred Heart, L.go F. Vito 1, 00168 Rome, Roma, Italy. ²Department of Public Health and Infectious Diseases, Sapienza Università di Roma, Rome, Italy. ³Department of Experimental Medicine, University of Perugia, via Gambuli 1, 06132 Perugia, Italy. ⁴Italian Ministry of Health, Rome, Italy.

Received: 26 September 2017 Accepted: 19 February 2018

Published online: 01 March 2018

References

- Porter ME. What is value in health care? *N Engl J Med*. 2010;363:2477–81.
- Porter ME, Olmsted Teisberg E. Redefining health care: creating value-based competition on results. Boston MA: Harvard Business Review Press; 2006.
- Porter ME, Lee TL. The strategy that will fix health care. *Harvard Business Review Press Book*; 2013. <https://hbr.org/2013/10/the-strategy-that-will-fix-health-care>. Accessed 30 July 2017.
- Joshi NP, Stahnisch FW, Noseworthy T. Reassessment of health technologies: obsolescence and waste. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009.
- Elshaug AG, Janet E, Hiller JE, Moss JR. Exploring policy-makers' perspectives on disinvestment from ineffective healthcare practices. *Int J Technol Assess Health Care*. 2008;24:1–9.
- EUnetHTA HTA definition. <http://www.eunetha.eu/about-us/faq#t287n73>. Accessed 30 July 2017.
- Henshal C, Schuller T, Mardhani-Bayne L. Using health technology assessment to support optimal use of Technologies in Current Practice: the challenge of "disinvestment". *Int J Technol Assess Health Care*. 2012;28(3):203–10.

8. Gerdvilaite J, Nachtnebel A. Disinvestment. Overview of disinvestment experiences and challenges in selected countries. 2011. <http://eprints.hta.lbg.ac.at/926/>. Accessed 27 July 2015.
9. Mayer J, Nachtnebel A. Identification of ineffective interventions and technologies: existing models and their implementation. 2013. <http://eprints.hta.lbg.ac.at/1014/>. Accessed 27 July 2015.
10. Cerbo M. Methods for investments/ disinvestments and distribution of health technologies in Italian regions. 2012-2013. <http://www.agenas.it/innovazione-hta-e-dispositivi-medicini/methods-for-investments-disinvestments-and-distribution-of-health-technologies-in-italian-regions>. Accessed July 2017.
11. Ruano Raviña A, Velasco González M, Varela Lema, Cerdá Mota T, Ibarгойen Roteta N, Gutiérrez Ibarluzea I, et al. Identification, prioritisation and assessment of obsolete health technologies. 2007. <https://www.sergas.es/docs/Avalia-t/ObsoleteTechMemFinal.pdf>. Accessed 27 July 2015
12. García-Armestoa S, Campillo-Artero C, Bernal-Delgado E. Disinvestment in the age of cost-cutting sound and fury. Tools for the Spanish National Health System. *Health Policy*. 2013;110:180–5.
13. Hollingworth W, Rooshenas L, Busby J, Hine CE, Badrinath P, Whiting PF, et al. Using clinical practice variations as a method for commissioners and clinicians to identify and prioritise opportunities for disinvestment in health care: a cross-sectional study, systematic reviews and qualitative study. 2015; 3(13) <https://njl-admin.nihr.ac.uk/document/download/2003763>. Accessed 27 July 2015
14. MaCSWise group of the Scottish Health Technologies Group (SHTG). MaCSWise - making choices spending wisely- a report of current practice in NHSScotland relating to National Institute of health and clinical excellence cost-saving recommendations. 2012. http://www.healthcareimprovementscotland.org/our_work/technologies_and_medicines/shtg.aspx. Accessed 27 July 2015
15. Healthcare Improvement Scotland development; Members of the SHTG evidence review committee team. What approaches have been taken and efforts made to ensure public involvement in decision making relating to potential disinvestment in healthcare interventions and technologies? 2013. <http://www.crd.york.ac.uk/CRDWeb/ShowRecord.asp?ID=32013000499>. Accessed 27 July 2015.
16. NICE- NHS- National Institute for Health and Clinical Excellence. Do not do recommendations. <https://www.nice.org.uk/>. Accessed 27 July 2015.
17. SHTG team. SHTG topic generation workshop. 2013. <http://www.healthcareimprovementscotland.org/>. Accessed 27 July 2015.
18. Grilli R, Espin J, Florindi F, De Lorenzo F. Policy paper on enhancing the value of cancer care through a more appropriate use of healthcare interventions. *Cancer Control Joint Action*. 2017; https://cancercontrol.eu/archived/uploads/PolicyPapers27032017/Policy_Paper_3_Enhancing.pdf . Accessed 18 Sept 2017
19. Health Policy Advisory Committee on Technology. Disinvestment in Australia and New Zealand. 2013.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit



Terms and Conditions

Springer Nature journal content, brought to you courtesy of Springer Nature Customer Service Center GmbH (“Springer Nature”).

Springer Nature supports a reasonable amount of sharing of research papers by authors, subscribers and authorised users (“Users”), for small-scale personal, non-commercial use provided that all copyright, trade and service marks and other proprietary notices are maintained. By accessing, sharing, receiving or otherwise using the Springer Nature journal content you agree to these terms of use (“Terms”). For these purposes, Springer Nature considers academic use (by researchers and students) to be non-commercial.

These Terms are supplementary and will apply in addition to any applicable website terms and conditions, a relevant site licence or a personal subscription. These Terms will prevail over any conflict or ambiguity with regards to the relevant terms, a site licence or a personal subscription (to the extent of the conflict or ambiguity only). For Creative Commons-licensed articles, the terms of the Creative Commons license used will apply.

We collect and use personal data to provide access to the Springer Nature journal content. We may also use these personal data internally within ResearchGate and Springer Nature and as agreed share it, in an anonymised way, for purposes of tracking, analysis and reporting. We will not otherwise disclose your personal data outside the ResearchGate or the Springer Nature group of companies unless we have your permission as detailed in the Privacy Policy.

While Users may use the Springer Nature journal content for small scale, personal non-commercial use, it is important to note that Users may not:

1. use such content for the purpose of providing other users with access on a regular or large scale basis or as a means to circumvent access control;
2. use such content where to do so would be considered a criminal or statutory offence in any jurisdiction, or gives rise to civil liability, or is otherwise unlawful;
3. falsely or misleadingly imply or suggest endorsement, approval, sponsorship, or association unless explicitly agreed to by Springer Nature in writing;
4. use bots or other automated methods to access the content or redirect messages
5. override any security feature or exclusionary protocol; or
6. share the content in order to create substitute for Springer Nature products or services or a systematic database of Springer Nature journal content.

In line with the restriction against commercial use, Springer Nature does not permit the creation of a product or service that creates revenue, royalties, rent or income from our content or its inclusion as part of a paid for service or for other commercial gain. Springer Nature journal content cannot be used for inter-library loans and librarians may not upload Springer Nature journal content on a large scale into their, or any other, institutional repository.

These terms of use are reviewed regularly and may be amended at any time. Springer Nature is not obligated to publish any information or content on this website and may remove it or features or functionality at our sole discretion, at any time with or without notice. Springer Nature may revoke this licence to you at any time and remove access to any copies of the Springer Nature journal content which have been saved.

To the fullest extent permitted by law, Springer Nature makes no warranties, representations or guarantees to Users, either express or implied with respect to the Springer nature journal content and all parties disclaim and waive any implied warranties or warranties imposed by law, including merchantability or fitness for any particular purpose.

Please note that these rights do not automatically extend to content, data or other material published by Springer Nature that may be licensed from third parties.

If you would like to use or distribute our Springer Nature journal content to a wider audience or on a regular basis or in any other manner not expressly permitted by these Terms, please contact Springer Nature at

onlineservice@springernature.com